PatientPlus articles are written by UK doctors and are based on research evidence, UK and European Guidelines. They are designed for health professionals to use, so you may find the language more technical than the condition leaflets.
Bartonella spp. are Gram-negative bacteria and are facultative intracellular parasites. Three species of the genus Bartonella are known to be important causes of human disease, although other species are increasingly being recognised as important. Bartonella are associated with an increasing range of diseases. The range of infection varies from mild lymphadenopathy seen in cat scratch disease to life-threatening systemic disease in immunocompromised patients.
Bartonella spp. have been isolated from a variety of mammalian species, most often rodents, ruminants and carnivores. Transmission is generally considered to be by arthropod vectors. Infections caused by Bartonella spp. include:
- Cat-scratch disease: Bartonella henselae.
- Trench fever: Bartonella quintana.
- Bacillary angiomatosis: B. henselae and B. quintana.
- Oroya fever and verruga peruana: Bartonella bacilliformis.
Cat scratch disease
See separate Cat Scratch Disease article.
Synonyms: shinbone fever, five-day fever, Wolhynia fever, quintana fever, His-Werner disease
- Add notes to any clinical page and create a reflective diary
- Automatically track and log every page you have viewed
- Print and export a summary to use in your appraisal
- It is caused by B. quintana. Urban trench fever is now seen in alcoholics and the homeless.
- Poor sanitation and lack of personal hygiene strongly correlate with transmission by the body louse Pediculus humanus.
- Fever develops after an incubation period of a few days to a month. Usually, several episodes of fever develop and each episode lasts about five days.
- Other symptoms include joint, bone and muscle pain, headache, dizziness and pain behind the eyes. Some patients have diffuse symptoms without fever.
- It may cause culture-negative endocarditis.
- On examination there are injected conjunctivae, nystagmus, hepatosplenomegaly, lymphadenopathy, a maculopapular rash and tender muscles and joints.
- Other causes of fever, headache, focal neurology and lymphadenopathy - eg, cytomegalovirus (CMV), HIV seroconversion.
- Other causes of culture-negative endocarditis include legionellosis, Q Fever and slow-growing streptococci.
Persistent bacteraemia with B. henselae may develop in people with AIDS.
Usually self-limiting. Trench fever re-infection may occur within 3-6 months because antibodies do not give full protection.
Bacillary angiomatosis and peliosis hepatis
Both B. henselae and B. quintana may cause bacillary angiomatosis, which most often occurs in HIV-positive patients. Patients should therefore have HIV antibodies and CD4 lymphocyte counts checked.
Bacillary angiomatosis is characterised by the proliferation of blood vessels, resulting in them forming tumour-like masses in the skin and other organs.
Bacillary angiomatosis is often associated with peliosis hepatis, which is characterised by multiple blood-filled cavities throughout the liver. Peliosis occasionally affects other parts of the body - eg, the spleen.
- Symptoms depend on the anatomical site involved and may include fever, tender lymphadenopathy and skin lesions.
- Lesions are often dark purple and resemble Kaposi's sarcoma.
- There may be enlargement of the liver, lymph nodes or spleen.
- Endocarditis is sometimes associated with Bartonella spp. infection (including B. henselae, B. quintana, Bartonella elizabethae).
- Homelessness and alcoholism are risk factors for B. quintana endocarditis.
- Bartonella encephalopathies are rare in patients with normal immunity but may occur in HIV-positive patients, especially with B. henselae and B. quintana infection. Features include meningoencephalitis, encephalopathy and neuropsychiatric disorders.
- B. henselae osteomyelitis has been reported.
- FBC usually demonstrates anaemia and LFTs show elevated serum alkaline phosphatase.
- Untreated patients have a high mortality.
- Immunocompromised patients with bacillary angiomatosis or peliosis hepatis respond well to antibiotics.
- Relapses are common.
Oroya fever and verruga peruana
Synonyms: Carrión's disease (Oroya fever); Peruvian wart (verruga peruana)
Oroya fever occurs in the acute phase of infection and the lesions of verruga peruana occur in the chronic delayed stage of infection.
B. bacilliformis is common in the Peruvian Andes and transmission is limited to elevations of 1,000-3,000 m because of the habitat of the sand fly vector.
- Bacteraemia in Oroya fever begins 3-12 weeks after a sand fly bite.
- May be mild where endemic (Andean Peru, Ecuador, Colombia, Chile, Bolivia and Guatemala) but may be severe in newly infected patients, with profound haemolytic anaemia, which is often fatal if untreated.
- Severe illness causes fever, headache, dyspnoea, mental state changes and seizures.
- Weeks or months later, untreated survivors develop verruga peruana lesions (angiomatous skin nodules), which begin as small nodules and then grow. They then form vascular lesions, which ulcerate, bleed and then heal by fibrosis over several months.
- Routine blood tests show haemolytic anaemia, thrombocytopenia and abnormal LFTs.
- The mortality and morbidity of acute infection are variable and the mortality associated with verruga peruana is very low.
- Persistent bacteraemia may occur in survivors.
- Microscopic examination of Giemsa-stained blood smears is used to detect B. bacilliformis in patients who may have Oroya fever.
- Other Bartonella species are visible only with silver stains (if they stain at all) and these stains are not specific.
- Cultures, particularly blood cultures, are often unhelpful for the diagnosis of Bartonella spp. infection.
- Cultures may be useful in patients who have other manifestations of either B. henselae or B. quintana infection, including fever of unknown origin, neuroretinitis, encephalitis, culture-negative endocarditis and peliosis or bacillary angiomatosis. Fresh media are required to increase the chance of isolation.
- Antibiotic susceptibility is not routinely tested in patients with bartonellosis because susceptibility studies may fail to predict response to therapy.
- Serology testing is the most cost-effective method to confirm the diagnosis in most patients with bartonellosis but there may be cross-reactivity with other bacteria (eg, other bartonellae, Chlamydia spp., Coxiella spp.) and serology testing may be unhelpful with immunocompromised patients.
- Some patients never develop detectable antibodies. However, the serology results of some patients remain positive long after exposure and recovery from their illness.
- Polymerase chain reaction (PCR):
- PCR genome testing is sensitive and specific but difficult to perform.
- PCR has played an important role in the diagnosis of Bartonella endocarditis. In cases of suspected Bartonella endocarditis, PCR on cardiac valve tissue is very sensitive and is not affected by antibiotic treatment prior to surgery.
- Because of the cross-reactivity between Bartonella spp. and other bacteria, PCR analysis of tissue and body fluid is the most specific test, especially in identifying distinct genotypes.
- CT scanning of the chest and abdomen may reveal mediastinal, retroperitoneal or mesenteric lymph node enlargement.
- In patients with bacillary angiomatosis/peliosis, CT scanning or MRI of the involved organ shows the enhancing lesions (eg, brain, liver). Radiography of the bone may show osteolytic lesions and bone destruction.
- Doxycycline is given for at least four weeks and a longer course is recommended for immunocompromised patients and when the liver or other organs are involved. Chloramphenicol may be used in severe cases.
- Bartonella endocarditis: the recommended treatment is doxycycline for six weeks, with gentamicin for two weeks. Surgical resection of heart valves is usually required. Mortality rate of Bartonella endocarditis is 30%.
Bacillary angiomatosis and peliosis hepatis
- Effective antibiotics include erythromycin, doxycycline, azithromycin, clarithromycin or a fluoroquinolone.
- Doxycycline combined with rifampin is effective for patients with severe disease but treatment is often required for three months or longer.
Oroya fever and verruga peruana
- Either chloramphenicol or doxycycline is effective and needs to be given for at least one week. Chloramphenicol is usually reserved for severe cases.
Further reading & references
- Maguina C, Guerra H, Ventosilla P; Bartonellosis. Clin Dermatol. 2009 May-Jun;27(3):271-80.
- Biswas S, Rolain JM; Bartonella infection: treatment and drug resistance. Future Microbiol. 2010 Nov;5:1719-31.
- Adamska M; (Bartonella spp. as a zoonotic pathogens transmitting by blood-feeding Wiad Parazytol. 2010;56(1):1-9.
- Foucault C, Barrau K, Brouqui P, et al; Bartonella quintana Bacteremia among Homeless People. Clin Infect Dis. 2002 Sep 15;35(6):684-9. Epub 2002 Aug 20.
- Ohl ME, Spach DH; Bartonella quintana and urban trench fever. Clin Infect Dis. 2000 Jul;31(1):131-5. Epub 2000 Jul 25.
- Justa RF, Carneiro AB, Rodrigues JL, et al; Bacillary angiomatosis in HIV-positive patient from Northeastern Brazil: a case report. Rev Soc Bras Med Trop. 2011 Oct;44(5):641-3.
- Maguina C, Garcia PJ, Gotuzzo E, et al; Bartonellosis (Carrion's disease) in the modern era. Clin Infect Dis. 2001 Sep 15;33(6):772-9. Epub 2001 Aug 10.
- CDC Infection 2012 (Cat Scratch Disease, Trench Fever, and Carrión’s Disease) overview
- Siciliano RF, Strabelli TM, Zeigler R, et al; Infective endocarditis due to Bartonella spp. and Coxiella burnetii: experience at a cardiology hospital in Sao Paulo, Brazil. Ann N Y Acad Sci. 2006 Oct;1078:215-22.
- Prutsky G, Domecq JP, Mori L, et al; Treatment outcomes of human bartonellosis: a systematic review and meta-analysis. Int J Infect Dis. 2013 Oct;17(10):e811-9. doi: 10.1016/j.ijid.2013.02.016. Epub 2013 Apr 18.
- Angelakis E, Raoult D; Pathogenicity and treatment of Bartonella infections. Int J Antimicrob Agents. 2014 Jul;44(1):16-25. doi: 10.1016/j.ijantimicag.2014.04.006. Epub 2014 May 9.
- Breitschwerdt EB; Bartonellosis: one health perspectives for an emerging infectious disease. ILAR J. 2014;55(1):46-58. doi: 10.1093/ilar/ilu015.
Disclaimer: This article is for information only and should not be used for the diagnosis or treatment of medical conditions. EMIS has used all reasonable care in compiling the information but make no warranty as to its accuracy. Consult a doctor or other health care professional for diagnosis and treatment of medical conditions. For details see our conditions.
Dr Colin Tidy
Dr Roger Henderson
Dr Colin Tidy